Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 17;11(4):e006070. doi: 10.1136/jitc-2022-006070

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

BRD4 and mismatch repair proteins expression are correlated across cancer lineages (A–B) mRNA expression (A) and protein levels (B) data in TCGA pan-cancer were obtained and the correlations of mRNA expression between BRD4 with MLH1, MSH2, MSH6, and PMS2 (A), and the correlations of protein levels of BRD4 with MSH2 and MSH6 were performed by Pearson’s correlation analyses (B). Color indicates coefficients calculated by Pearson’s correlation test (*, p<0.05; **, p<0.01; ***, p<0.001). (C) Proteomics data in CPTAC data was obtained and Pearson’s correlation analyses of BRD4 with MLH1, MSH2, MSH6, and PMS2 was performed. Color indicates coefficients calculated by Pearson’s correlation test (*, p<0.05; **, p<0.01; ***, p<0.001). (D) Representative IHC images (200×) of BRD4, MLH1, MSH2, MSH6, and PMS2 (left) and correlation between BRD4 IHC score and the sum of MLH1, MSH2, MSH6, and PMS2 IHC scores (right) in high-grade serous ovarian cancer tissues. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; BRD4, bromodomain containing 4; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; CPTAC, Clinical Proteomic Tumor Analysis Consortium; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; IHC, immunohistochemistry; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; MLH1, mutL homologue 1; mRNA, messenger RNA; MSH2, mutS homologue 2; MSH6, mutS homologue 6; OV, ovarian cancer; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PMS2, PMS1 homolog 2, mismatch repair system component; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; RPPA, reverse phase protein arrays; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TCGA, The Cancer Genome Atlas; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.